Navigation Links
ARIUS announces second quarter fiscal 2008 financial results
Date:7/11/2008

riods was primarily the result of the recognition of product and research contract revenue from the Takeda collaboration and the recognition of licensing fee revenue for an extension fee payment under the agreement with PDL Biopharma Inc.

For the six-month period ended May 31, 2008, the Company's interest income decreased to $176,512 compared to $381,407 for the same period in fiscal 2007. For the three-month period ended May 31, 2008, the Company's interest income decreased to $69,720 compared to $181,484 for the same period in fiscal 2007. The decrease for both periods was primarily the result of lower average cash and investment balances.

For the six-month period ended May 31, 2008, the Company's research and development costs increased to $5,933,367 compared to $4,059,931 for the same period in fiscal 2007. For the three-month period ended May 31, 2008, the Company's research and development costs increased to $3,337,461 compared to $2,102,603 for the same period in fiscal 2007. The increases were primarily the result of an increase in staffing levels related to an overall increase in activity as the Company is preparing three products for the clinic, accompanied by increased patent and licensing activity and an increase in stock option remuneration expense.

For the six-month period ended May 31, 2008, the Company's general and administrative expenses increased to $2,170,683 compared to $1,437,009 for the same period in fiscal 2007. For the three-month period ended May 31, 2008, the Company's general and administrative expenses increased to $1,149,402 compared to $762,673 for the same period in fiscal 2007. The increases were primarily the result of an increase in staffing levels, consulting fees, legal expenses and stock option remuneration expense.

As at May 31, 2008, ARIUS' cash and cash equivalents, and net working capital position were $8,543,124 and $5,807,638, respectively, compared with November 30, 2007 cash and cash equivale
'/>"/>

SOURCE ARIUS Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. ARIUS presents new findings for anti-cancer antibody programs at AACR
2. ARIUS announces first quarter fiscal 2008 financial results
3. ARIUS 2008 Annual and Special Meeting of Shareholders
4. ARIUS recognized for entrepreneurial excellence
5. ARIUS announces five abstracts selected for presentation at 2008 AACR Annual Meeting
6. ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells
7. Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody
8. ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody
9. ARIUS announces fourth quarter and year-end fiscal 2007 financial results
10. Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
11. ARIUS to Hold Fourth Quarter and Year End 2007 Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/26/2014)... (PRWEB) October 26, 2014 The ... Routers, ADC, Network Security Equipment, WAN Optimization Appliances]: ... and segments the data center networking market into ... of revenues. The report also identifies the factors ... opportunities impacting it along with the future roadmaps. ...
(Date:10/25/2014)... 25, 2014 The report “Adipic ... by Geography - Global Trends & Forecast to ... respect to market drivers, opportunities, and trends in ... and 27 figures spread through 217 slides and ... Trends & Forecast to 2019”., http://www.marketsandmarkets.com/Market-Reports/adipic-acid-269.html , ...
(Date:10/25/2014)... BioProcess International (BPI), a business-to-business ... BioProcess International Awards. The awards celebrate the outstanding ... technology applications that will allow the industry to ... patient base. , Winners and finalists were honored ... entertaining and exciting awards dinner and ceremony yesterday ...
(Date:10/25/2014)... Iowa (PRWEB) October 24, 2014 ... Perdue plans to more than double the acreage ... in geographies supplying its soybean crush facility in ... from this program will target several markets including ... alternatives with good performance. , For the 2015 ...
Breaking Biology Technology:Data Center Networking Market by Ethernet Switches, SAN & Routers Worth $21.85 Billion by 2018 - New Report by MarketsandMarkets 2Data Center Networking Market by Ethernet Switches, SAN & Routers Worth $21.85 Billion by 2018 - New Report by MarketsandMarkets 3Data Center Networking Market by Ethernet Switches, SAN & Routers Worth $21.85 Billion by 2018 - New Report by MarketsandMarkets 4Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 2Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 3Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 4BioProcess International Announces Winners of the 2014 BioProcess International Awards 2BioProcess International Announces Winners of the 2014 BioProcess International Awards 3BioProcess International Announces Winners of the 2014 BioProcess International Awards 4BioProcess International Announces Winners of the 2014 BioProcess International Awards 5DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 2DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 3DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 4
... Quarter 2009 Financial ResultsVANCOUVER, April 16 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, ... a conference call discussing its financial results for the first ... at 11:00 AM ET (8:00 AM Pacific)., ... is as, follows:, North ...
... Aspheric NTIOL Implanted through the Smallest Micro-Incision using ... Assist Ophthalmic PracticesMONROVIA, Calif., April 16 STAAR ... leading developer, manufacturer and marketer of minimally invasive ... Afinity Collamer Aspheric Single Piece New Technology Intraocular ...
... April 15 Cytopia Limited (ASX: CYT) announced that ... agent (VDA) CYT997 at the forthcoming 100th Annual Meeting ... Colorado, USA. Dr David Segal, Principal Scientist at Cytopia, ... Research: Experimental and Molecular Therapeutics 2 poster session ...
Cached Biology Technology:STAAR Surgical Releases Afinity(TM) Collamer(R) Aspheric Single Piece NTIOL 2STAAR Surgical Releases Afinity(TM) Collamer(R) Aspheric Single Piece NTIOL 3STAAR Surgical Releases Afinity(TM) Collamer(R) Aspheric Single Piece NTIOL 4STAAR Surgical Releases Afinity(TM) Collamer(R) Aspheric Single Piece NTIOL 5Cytopia Presentation on VDA CYT997 at AACR Conference 2
(Date:10/29/2014)... ceremony held in New York City on September 19, ... American Cancer Society Professor of Genome Sciences and Medicine ... Honorary Doctor of Philosophy of Tel Aviv University, was ... Science. , In addition to her honorary degree from ... the TAU School of Medicine, and for the past ...
(Date:10/29/2014)... One kind of stem cell, those referred to as ... There is apparently nothing that differentiates these cells from ... namely they retain the capacity to become stem cells ... liver, an organ that hosts cells that stimulate tissue ... the case of a transplant. Knowledge of the ...
(Date:10/29/2014)... living world compete with members of their own ... they invest into their competitive ability. Some individuals ... to high-quality resources, while others seem to avoid ... resources that are left over for them. Moreover, ... societies seems to fluctuate considerably over time. A ...
Breaking Biology News(10 mins):Geneticist and humanitarian: Prof. Mary-Claire King receives Lasker Award 2A mechanism that allows a differentiated cell to reactivate as a stem cell revealed 2Evolution of competitiveness 2Evolution of competitiveness 3
... international collaborators have discovered the key to overcoming three ... growers worldwide in excess of AUS$7.8 billion. In ... Science , scientists from CSIRO Plant Industry, the University ... Center have identified a wheat gene sequence which provides ...
... Cardiovascular Research Institute, Colchester, Vermont have found that ... inhibitor type-1 (PAI-1) is profibrotic. The results, ... Experimental Biology and Medicine , implicate PAI-1 ... 2 diabetes, as a factor contributing to the ...
... Princeton, NJ February 23, 2009 - A new ... the Intergovernmental Panel on Climate Change (IPCC) 2001 Third ... increase in average global temperatures due to greenhouse gas ... of global concern. The study, published in the ...
Cached Biology News:Saving wheat crops worldwide 2Plasminogen activator inhibitor type-1 -- a potential link between heart failure and diabetes 2Lower increases in global temps could lead to greater impacts than previously thought, study finds 2Lower increases in global temps could lead to greater impacts than previously thought, study finds 3
Metamine is an autonomous data mining tool that extends the capabilities of conventional research teams. It is a proactive agent that searches for significant results buried within the GeNet data rep...
Compound(s) tested through a broad panel of 38 ligand binding and enzyme assays targeting the Central Nervous System. Used to determine selecitivty and potential CNS-Side Effect liabilities of compo...
... Endogens Screening Sets contain the ... develop five colorimetric sandwich ELISA plates ... in 100 l/well of cell culture ... and Detection Antibodies, Recombinant Standard (5 ...
... The organic acid analysis standard ... six organic salts; molecular weights ... This standard is provided for ... column and the organic acid ...
Biology Products: